These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29357008)

  • 1. Matricellular CCN6 (WISP3) protein: a tumor suppressor for mammary metaplastic carcinomas.
    Tran MN; Kleer CG
    J Cell Commun Signal; 2018 Mar; 12(1):13-19. PubMed ID: 29357008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.
    Martin EE; Huang W; Anwar T; Arellano-Garcia C; Burman B; Guan JL; Gonzalez ME; Kleer CG
    Oncogene; 2017 Apr; 36(16):2275-2285. PubMed ID: 27819674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.
    McMullen ER; Gonzalez ME; Skala SL; Tran M; Thomas D; Djomehri SI; Burman B; Kidwell KM; Kleer CG
    Breast Cancer Res Treat; 2018 Dec; 172(3):577-586. PubMed ID: 30220054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The matricellular protein CCN6 differentially regulates mitochondrial metabolism in normal epithelium and in metaplastic breast carcinomas.
    Tran M; Leflein SA; Gonzalez ME; Kleer CG
    J Cell Commun Signal; 2022 Sep; 16(3):433-445. PubMed ID: 34811632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells.
    Huang W; Martin EE; Burman B; Gonzalez ME; Kleer CG
    Oncotarget; 2016 May; 7(18):25180-93. PubMed ID: 26933820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer.
    Kleer CG; Zhang Y; Merajver SD
    Cells Tissues Organs; 2007; 185(1-3):95-9. PubMed ID: 17587813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells.
    Zhang Y; Pan Q; Zhong H; Merajver SD; Kleer CG
    Breast Cancer Res; 2005; 7(6):R1080-9. PubMed ID: 16457688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.
    Huang W; Gonzalez ME; Toy KA; Banerjee M; Kleer CG
    Cancer Res; 2010 Apr; 70(8):3340-50. PubMed ID: 20395207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCN6: a modulator of breast cancer progression.
    Leask A
    J Cell Commun Signal; 2016 Jun; 10(2):163-4. PubMed ID: 27086280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of CCN6 in breast cancer invasion.
    Lorenzatti G; Huang W; Kleer CG
    Cellscience; 2009 Oct; 6(2):146-157. PubMed ID: 29071006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer.
    Pal A; Huang W; Li X; Toy KA; Nikolovska-Coleska Z; Kleer CG
    Cancer Res; 2012 Sep; 72(18):4818-28. PubMed ID: 22805309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCN6 (WISP3): a new anti-cancer therapy?
    Leask A
    J Cell Commun Signal; 2010 Dec; 4(4):199-200. PubMed ID: 21234127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual roles of CCN proteins in breast cancer progression.
    Kleer CG
    J Cell Commun Signal; 2016 Sep; 10(3):217-222. PubMed ID: 27520547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCN6: a novel method of aTAKing cancer.
    Leask A
    J Cell Commun Signal; 2013 Jun; 7(2):161-2. PubMed ID: 23292930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On how CCN6 suppresses breast cancer growth and invasion.
    Huang W; Pal A; Kleer CG
    J Cell Commun Signal; 2012 Mar; 6(1):5-10. PubMed ID: 21842227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.
    Kleer CG; Zhang Y; Pan Q; Merajver SD
    Neoplasia; 2004; 6(2):179-85. PubMed ID: 15140407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCN6 knockdown disrupts acinar organization of breast cells in three-dimensional cultures through up-regulation of type III TGF-β receptor.
    Pal A; Huang W; Toy KA; Kleer CG
    Neoplasia; 2012 Nov; 14(11):1067-74. PubMed ID: 23226100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metaplastic Breast Carcinoma: Update on Histopathology and Molecular Alterations.
    McMullen ER; Zoumberos NA; Kleer CG
    Arch Pathol Lab Med; 2019 Dec; 143(12):1492-1496. PubMed ID: 31765246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma.
    Koker MM; Kleer CG
    Am J Surg Pathol; 2004 Nov; 28(11):1506-12. PubMed ID: 15489655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metaplastic breast carcinoma: a retrospective study of 26 cases.
    Zhou X; Wu X; Wang L; Guo J; Wu Q; Song W; Zhao Y; Feng Z; Wu S; Zhang L; Gong X
    Int J Clin Exp Pathol; 2021; 14(3):355-362. PubMed ID: 33786152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.